HHS is seeking to penalize Boehringer Ingelheim for reducing 340B discounts, the department said in a March 29 letter to the drugmaker.
Read the full post on Becker's Hospital Review - Healthcare News
HHS to fine Boehringer Ingelheim for curtailing 340B discounts
